1. Home
  2. HSHP vs LUNG Comparison

HSHP vs LUNG Comparison

Compare HSHP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSHP
  • LUNG
  • Stock Information
  • Founded
  • HSHP 2021
  • LUNG 1995
  • Country
  • HSHP Bermuda
  • LUNG United States
  • Employees
  • HSHP N/A
  • LUNG N/A
  • Industry
  • HSHP
  • LUNG Industrial Specialties
  • Sector
  • HSHP
  • LUNG Health Care
  • Exchange
  • HSHP Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • HSHP 287.7M
  • LUNG 124.0M
  • IPO Year
  • HSHP 2023
  • LUNG 2020
  • Fundamental
  • Price
  • HSHP $6.16
  • LUNG $2.78
  • Analyst Decision
  • HSHP
  • LUNG Buy
  • Analyst Count
  • HSHP 0
  • LUNG 6
  • Target Price
  • HSHP N/A
  • LUNG $11.53
  • AVG Volume (30 Days)
  • HSHP 207.8K
  • LUNG 311.3K
  • Earning Date
  • HSHP 08-20-2025
  • LUNG 07-30-2025
  • Dividend Yield
  • HSHP 7.14%
  • LUNG N/A
  • EPS Growth
  • HSHP 185.76
  • LUNG N/A
  • EPS
  • HSHP 0.28
  • LUNG N/A
  • Revenue
  • HSHP $121,972,000.00
  • LUNG $87,473,000.00
  • Revenue This Year
  • HSHP $11.22
  • LUNG $18.02
  • Revenue Next Year
  • HSHP $25.90
  • LUNG $18.17
  • P/E Ratio
  • HSHP $23.39
  • LUNG N/A
  • Revenue Growth
  • HSHP 107.17
  • LUNG 19.84
  • 52 Week Low
  • HSHP $4.29
  • LUNG $2.50
  • 52 Week High
  • HSHP $9.13
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • HSHP 53.69
  • LUNG 41.83
  • Support Level
  • HSHP $5.76
  • LUNG $2.52
  • Resistance Level
  • HSHP $6.26
  • LUNG $2.84
  • Average True Range (ATR)
  • HSHP 0.17
  • LUNG 0.16
  • MACD
  • HSHP -0.07
  • LUNG 0.04
  • Stochastic Oscillator
  • HSHP 43.32
  • LUNG 46.36

About HSHP Himalaya Shipping Ltd.

Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: